2023
Bradykinin B2 receptor blockade and intradialytic hypotension
Gamboa J, Mambungu C, Clagett A, Nian H, Yu C, Ikizler T, Brown N. Bradykinin B2 receptor blockade and intradialytic hypotension. BMC Nephrology 2023, 24: 134. PMID: 37170244, PMCID: PMC10176680, DOI: 10.1186/s12882-023-03192-4.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor blockadeB2 receptor blockadeMaintenance hemodialysisBlood pressureReceptor blockersReceptor blockadeIntradialytic hypotensionBradykinin B2 receptor blockerLack of vasoconstrictionProduction of vasodilatorsSystolic blood pressureGroup of patientsCrossover clinical trialCommon clinical complicationHemodynamic effectsClinical complicationsContinuous infusionClinical trialsStratified analysisIcatibantHemodialysisPatientsHypotensionPlaceboCompensatory mechanisms
2020
Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis
Gamboa JL, Roshanravan B, Towse T, Keller CA, Falck AM, Yu C, Frontera WR, Brown NJ, Ikizler TA. Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis. Clinical Journal Of The American Society Of Nephrology 2020, 15: 926-936. PMID: 32591419, PMCID: PMC7341789, DOI: 10.2215/cjn.10320819.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAdultAgedDynaminsFemaleGlomerular Filtration RateHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMiddle AgedMitochondriaMuscle StrengthPhosphocreatinePhysical Functional PerformanceQuadriceps MuscleRenal DialysisRenal Insufficiency, ChronicSeverity of Illness IndexWalk TestConceptsMaintenance hemodialysisMarkers of inflammationAdipose tissue infiltrationOxidative stressPhysical performanceMitochondrial dysfunctionTissue infiltrationMitochondrial functionSkeletal muscle mitochondrial dysfunctionCKD stage 3Poor physical performanceSeverity of CKDMuscle mitochondrial dysfunctionIntermuscular adipose tissueSkeletal muscle biopsiesMagnetic resonance imagingWalk testHigh morbidityPhysical functionPhosphocreatine recoveryMultifactorial etiologyMuscle biopsyCKDHemodialysisPatients
2018
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis
Kaseda R, Tsuchida Y, Gamboa JL, Zhong J, Zhang L, Yang H, Dikalova A, Bian A, Davies S, Fogo AF, Linton MF, Brown NJ, Ikizler TA, Kon V. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. Nutrition Metabolism And Cardiovascular Diseases 2018, 28: 582-591. PMID: 29691148, PMCID: PMC5959764, DOI: 10.1016/j.numecd.2018.02.020.Peer-Reviewed Original ResearchConceptsAngiotensin receptor blockersHigh-density lipoproteinToll-like receptorsAnti-inflammatory effectsReceptor blockersCytokine responsesActivation of TLRsSerum amyloid A (SAA) levelsACE inhibitor effectsHigh cardiovascular riskAdvanced kidney diseaseMaintenance hemodialysis patientsInflammatory cytokine responseAnti-oxidative effectsACEI treatmentAtheroprotective actionARB treatmentCardiovascular eventsMaintenance hemodialysisAngiotensin actionCardiovascular riskHemodialysis patientsCellular superoxide productionHDL functionalityKidney disease
2015
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis – a randomized cross-over study
Gamboa JL, Pretorius M, Sprinkel KC, Brown NJ, Ikizler TA. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis – a randomized cross-over study. BMC Nephrology 2015, 16: 167. PMID: 26494370, PMCID: PMC4618919, DOI: 10.1186/s12882-015-0162-x.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseAngiotensin receptor blockersMaintenance hemodialysisCross-over studyADMA levelsAsymmetric dimethylarginineACE inhibitionADMA productionADMA concentrationsShort-term ACE inhibitionRandomized cross-over studyIntracellular ADMA concentrationStudy of patientsEffect of bradykininB2 receptor stimulationACE inhibitor-induced increaseInhibitor-induced increaseRamipril treatmentCardiovascular morbidityReceptor blockersEndothelial dysfunctionRenal diseaseBradykinin levelsBackgroundEndothelial dysfunctionDialysis session
2011
Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during Hemodialysis
Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ. Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during Hemodialysis. Journal Of The American Society Of Nephrology 2011, 23: 334-342. PMID: 22158433, PMCID: PMC3269170, DOI: 10.1681/asn.2011030287.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBlood CoagulationCD40 LigandCross-Over StudiesCytokinesDouble-Blind MethodFemaleHemodynamicsHumansInflammationKidney Failure, ChronicMaleMiddle AgedOxidative StressRamiprilRenal DialysisReninTetrazolesValineValsartanConceptsAngiotensin receptor blockersMaintenance hemodialysis patientsCardiovascular mortalityHemodialysis patientsACE inhibitorsGreater anti-inflammatory effectAngiotensin-Converting Enzyme InhibitionOxidative stressAngiotensin receptor blockadeIL-10 concentrationsD-dimer levelsIL-6 levelsProspective clinical trialsAnti-inflammatory effectsIL-1β concentrationsLevels of vWFSerial blood samplingCardiovascular eventsEndothelial dysfunctionCrossover studyWashout periodIsoprostane levelsClinical trialsDrug treatmentVWF levelsCombined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients
Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 2011, 80: 978-985. PMID: 21775975, PMCID: PMC3656595, DOI: 10.1038/ki.2011.228.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCardiovascular DiseasesDrug Therapy, CombinationFemaleHumansHypertensionKaplan-Meier EstimateKidney Failure, ChronicLogistic ModelsMaleMiddle AgedPropensity ScoreProportional Hazards ModelsRenal DialysisRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesConceptsAngiotensin receptor blockersAntihypertensive medicationsARB therapyCardiovascular deathChronic hemodialysisCardiovascular mortalityHazard ratioHemodialysis patientsRisk factorsBaseline cardiovascular risk factorsAngiotensin-converting enzyme inhibitionLarge dialysis providerCardiovascular risk factorsChronic hemodialysis patientsKaplan-Meier methodMortality hazard ratioAntihypertensive therapyReceptor blockersAntihypertensive agentsCox regressionCerebrovascular mortalityClinical trialsTreatment weightingObservational studyACEI
2009
Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis
Marney AM, Ma J, Luther JM, Ikizler TA, Brown NJ. Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis. Journal Of The American Society Of Nephrology 2009, 20: 2246-2252. PMID: 19628666, PMCID: PMC2754101, DOI: 10.1681/asn.2009050505.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1 antigenHoe 140Endogenous bradykininHemodialysis patientsMCP-1Receptor blocker HOE-140Placebo-controlled crossover studyOxidative stressChronic hemodialysis patientsMean arterial pressureCoronary artery diseaseKallikrein-kinin systemBradykinin receptor antagonismHeart rate responsePAI-1 antigenTissue plasminogen activatorEffect of dialysisEnd of dialysisProduction of bradykininInhibits platelet aggregationCardiovascular eventsHemodialysis populationArterial pressureArtery diseaseEndothelial release